ClinicalTrials.gg
CompletedNCT04777201AVONELLE-XUpdated Oct 24, 2025Results posted

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

A Phase 3 interventional study of Faricimab and Sham Procedure in Neovascular Age-related Macular Degeneration, sponsored by Hoffmann-La Roche. Completed at 251 sites in 27 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,036
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing faricimab in Macular Degeneration — 6 open to participants now, 7 under way, 2 of them phase 3. faricimab · Macular Degeneration.

Enrollment
Largest of 14
1,036 · median 57
Started
2021
the only one that year
Phase 3
3 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
5 of 14
Hoffmann-La Roche

Among the 14 studies testing faricimab in Macular Degeneration, this one has the largest enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 3rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

6 of the 14 studies testing faricimab in Macular Degeneration are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About faricimab

faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing faricimab in Macular Degeneration, or all of them as a file.
02

Study summary

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval (PTI) to participants with neovascular age-related macular degeneration (nAMD) who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or GR40844 (NCT03823300), also referred to as the parent studies. Eligible patients who consent to participate in this main study will be enrolled upon completion of the end-of-study visit in the parent study.

Additionally, there is a substudy that is being conducted. The aim of this substudy is to evaluate the impact of intravitreal faricimab on the health of the corneal endothelial cells in the study eyes of patients with nAMD to fulfill a U.S. Food and Drug Administration (FDA) post-marketing requirement. The fellow eyes of the same enrolled participants in the substudy will serve as the controls.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for the Main Study:

  • Previous enrollment in and completion of Study GR40306 (NCT03823287) or Study GR40844 (NCT03823300), without study or study drug discontinuation
  • For women of : agreement to remain abstinent or use , and agreement to refrain from donating eggs. Women must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for 3 months after the final dose of faricimab. Women must refrain from donating eggs during the same period.

Inclusion Criteria for the Substudy:

  • In addition to all inclusion criteria specified in the main Study GR42691, participants in the Substudy must meet the following criteria:
  • Sign an form for the Substudy
  • Must be able to participate for at least 48 weeks in the Substudy and have at least the first visit while enrolled in the main Study GR42691
  • A difference of \<10% in corneal endothelial cell density at screening between the two eyes as measured by specular microscopy and determined by the independent reading center

Exclusion Criteria for the Main Study:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab
  • Presence of other ocular diseases that give reasonable suspicion of a disease or condition that contraindicates the use of faricimab, that might affect interpretation of the results of the study or that renders the patient at high risk for treatment complications
  • Presence of other diseases, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of faricimab and that might affect interpretation of the results of the study or that renders the patient at high risk of treatment complications
  • History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the faricimab injections, study-related procedure preparations, dilating drops, or any of the anesthetic and antimicrobial preparations used by a patient during the study
  • Requirement for continuous use of any medications or treatments indicated as prohibited therapy

Exclusion Criteria for the Substudy:

In addition to the exclusion criteria specified in the main Study GR42691, patients will be excluded from this substudy if they meet any of the following exclusion criteria:

  • Prior and/or current administration of faricimab in the fellow (non-study) eye
  • Prior administration of brolucizumab in the fellow (non-study) eye

Exclusion Criteria in Either Eye for the Substudy:

  • Corneal endothelial cell density ≤1500 cells/mm2 in either eye at screening as determined by the independent corneal reading center
  • Fuchs endothelial corneal dystrophy Grade ≥2
  • Previous ocular trauma (blunt or penetrating) and/or corneal endothelial cell damage, including from blunt or surgical trauma (including complicated cataract surgery resulting in complicated lens placement such as anterior chamber intraocular lens, sulcus intraocular lens, aphakia, etc.)
  • Any ocular condition that precludes obtaining an analyzable specular microscopy image
  • Active or history of corneal edema
  • Any active or history of corneal dystrophies, excluding Fuchs endothelial corneal dystrophy Grade \<2
  • Active or history of iridocorneal endothelial syndrome
  • Active or history of pseudoexfoliation syndrome
  • Active or history of herpetic keratitis or kerato-uveitis (including herpes simplex virus and herpes zoster virus)
  • Intraocular laser therapy including selective laser trabeculoplasty, yttrium-aluminum garnet (YAG), prophylactic peripheral iridotomy within 1 year of screening, or YAG capsulotomy within 3 months of screening
  • Prior vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
  • Prior pars plana vitrectomy surgery
  • Previous intraocular device implantation excluding intraocular lenses
  • Cataract surgery within 6 months of screening or planned for during the study
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery. Other types of prior glaucoma surgery are allowed providing that the surgery occur more than 6 months before screening
  • Administration of topical Rho kinase inhibitors (e.g., Rhopressa eye drops) within 1 month prior to the screening visit
  • Contact lens wear in either eye within 2 months of screening
  • History of corneal transplantation, including partial-thickness corneal grafts (e.g., Descemet membrane endothelial keratoplasty, Descemet stripping endothelial keratoplasty)
  • Active or history of iridocorneal endothelial syndrome
  • Active or history of pseudoexfoliation syndrome
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,036 participants (actual)

Study arms

  • Experimental
    Main Study: Faricimab PTI

    Drug: Faricimab · Other: Sham Procedure · Drug: Anti-VEGF Therapy

  • Experimental
    Substudy: Faricimab PTI

    Drug: Faricimab · Drug: Anti-VEGF Therapy

Interventions

  • Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.

    Also known as: RO6867461, RG7716

  • OtherSham Procedure

    The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.

  • DrugAnti-VEGF Therapy

    At the discretion of the principal investigator, participants were allowed to have their fellow (non-study) eye treated with the standard of care anti-VEGF therapy (if needed) according to region-specific anti-VEGF prescribing information for the recommended dose and frequency of treatment.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale

    This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)

  2. Incidence of Ocular Adverse Events in the Fellow Eye

    This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity, and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)

  3. Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading Scale

    This is an analysis of participants with at least one non-ocular (systemic) adverse event (AE). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)

  4. Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year in the Study Eye as Compared With the Fellow Eye

    Specular microscopy was performed for both eyes prior to application of any topical ophthalmic anesthetic, tonometry, or any other study treatment on the same day for the evaluation of corneal endothelial cell (CEC) density. The 1-year timepoint was defined as the earliest substudy visit closest to Week 52 occurring between Week 48 and Week 64. Data (from both study eye and fellow eye) collected after the fellow eye's use of prohibited therapies-such as faricimab, brolucizumab, bevacizumab, and Port Delivery System implantation-were excluded from the corneal endothelial cell analysis.

    Time frame: Baseline and 1 year

Secondary outcomes

  1. Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at Week 24 in the Study Eye as Compared With the Fellow Eye

    Specular microscopy was performed for both eyes prior to application of any topical ophthalmic anesthetic, tonometry, or any other study treatment on the same day for the evaluation of corneal endothelial cell (CEC) density. The Week 24 timepoint was defined as the earliest substudy visit closest to Week 24 occurring between Week 20 and Week 28. Data (from both study eye and fellow eye) collected after the fellow eye's use of prohibited therapies-such as faricimab, brolucizumab, bevacizumab, and Port Delivery System implantation-were excluded from the corneal endothelial cell analysis.

    Time frame: Baseline and Week 24

07

Results

Posted Oct 24, 2025

Participant flow

A total of 1036 participants were enrolled in the main study, 7 of whom were excluded from analysis, resulting in a final analysis set of 1029 participants. A subgroup of 117 also participated concurrently in the substudy. Only 1 eye for each participant was assigned as the study eye in the prior parent studies, per the eligibility criteria, to receive study intervention; that study eye remained the same in this main study and substudy. The fellow (other) eye was not assigned to an intervention.

Main Study
Participant flow — Main Study
MilestoneMain Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTI
Started5245050
Safety-evaluable population5205050
Completed4534150
Not completed71900
Withdrew: Withdrawal by subject19270
Withdrew: Death13270
Withdrew: Subject missed the safety follow-up visit9100
Withdrew: Physician decision8100
Withdrew: Adverse event880
Withdrew: Lost to follow-up940
Withdrew: Reason not specified330
Withdrew: Lack of efficacy110
Withdrew: Protocol violation100
Substudy (Concurrent With Main Study)
Participant flow — Substudy (Concurrent With Main Study)
MilestoneMain Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTI
Started00117
Modified intent-to-treat and safety-evaluable population00113
Completed the year 1 substudy visit00104
Completed00107
Not completed0010
Withdrew: Withdrawal by subject004
Withdrew: Prohibited medication002
Withdrew: Adverse event001
Withdrew: Cataract surgery001
Withdrew: Lost to follow-up001
Withdrew: Physician decision001

Outcome measures

PrimaryIncidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale

This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
Reported as:
Count of participants · Participants
Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale
ParticipantsMain Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTI
Any Adverse Event (AE), Any Severity18820716
AEs by Severity: Mild11410611
AEs by Severity: Moderate58754
AEs by Severity: Severe13231
AEs by Severity: Missing330
Serious Adverse Event (SAE)18271
AE Leading to Withdrawal from Study Treatment450
Treatment-related AE8122
Treatment-related SAE131
Any AE of Special Interest (AESI)15211
AESI: Drop in Visual Acuity Score ≥30 Letters11161
AESI: Associated with Severe IOI120
AESI: Intervention Required to Prevent Permanent Vision Loss330
AESI: Suspected Transmission of Infectious Agent by Study Drug000
PrimaryIncidence of Ocular Adverse Events in the Fellow Eye

This is an analysis of participants with at least one ocular adverse event (AE) that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity, and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
Reported as:
Count of participants · Participants
Incidence of Ocular Adverse Events in the Fellow Eye
ParticipantsMain Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTI
Any Adverse Event (AE), Any Severity15714917
Serious Adverse Event (SAE)4111
Any AE of Special Interest (AESI)3111
AESI: Drop in Visual Acuity Score ≥30 Letters380
AESI: Associated with Severe IOI000
AESI: Intervention Required to Prevent Permanent Vision Loss031
AESI: Suspected Transmission of Infectious Agent by Study Drug000
PrimaryIncidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading Scale

This is an analysis of participants with at least one non-ocular (systemic) adverse event (AE). Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of the seriousness, severity (e.g., mild, moderate, or severe intensity), and causality for each AE. AEs of special interest (AESI) included the following: Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, are associated with severe intraocular inflammation (IOI), or require surgical or medical intervention to prevent permanent loss of sight; suspected transmission of an infectious agent by the study drug; and, cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
Reported as:
Count of participants · Participants
Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading Scale
ParticipantsMain Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTI
Any Adverse Event (AE), Any Severity34333741
AE by Severity: Mild12212015
AE by Severity: Moderate13812417
AE by Severity: Severe83939
Serious Adverse Event (SAE)11012713
AE Leading to Withdrawal from Study Treatment390
Any AE of Special Interest (AESI)000
AESI: Elevated ALT or AST with Either Elevated Bilirubin or Clinical Jaundice000
PrimarySubstudy: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year in the Study Eye as Compared With the Fellow Eye

Specular microscopy was performed for both eyes prior to application of any topical ophthalmic anesthetic, tonometry, or any other study treatment on the same day for the evaluation of corneal endothelial cell (CEC) density. The 1-year timepoint was defined as the earliest substudy visit closest to Week 52 occurring between Week 48 and Week 64. Data (from both study eye and fellow eye) collected after the fellow eye's use of prohibited therapies-such as faricimab, brolucizumab, bevacizumab, and Port Delivery System implantation-were excluded from the corneal endothelial cell analysis.

Time frame:
Baseline and 1 year
Reported as:
Mean · Percent change in cell density
Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year in the Study Eye as Compared With the Fellow Eye
Percent change in cell densitySubstudy: Faricimab PTI in the Study EyeSubstudy: Fellow Eye
Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year in the Study Eye as Compared With the Fellow Eye-0.51 (-1.68 to 0.65)-0.71 (-1.53 to 0.10)
Statistical analysis
  • Substudy: Faricimab PTI in the Study Eye vs Substudy: Fellow Eye · Paired t-test · p = 0.7702 · Mean difference (final values): 0.20 · 95% CI -1.14 to 1.54Difference is the result of study eye minus fellow eye.
SecondarySubstudy: Percent Change in Corneal Endothelial Cell Density From Baseline at Week 24 in the Study Eye as Compared With the Fellow Eye

Specular microscopy was performed for both eyes prior to application of any topical ophthalmic anesthetic, tonometry, or any other study treatment on the same day for the evaluation of corneal endothelial cell (CEC) density. The Week 24 timepoint was defined as the earliest substudy visit closest to Week 24 occurring between Week 20 and Week 28. Data (from both study eye and fellow eye) collected after the fellow eye's use of prohibited therapies-such as faricimab, brolucizumab, bevacizumab, and Port Delivery System implantation-were excluded from the corneal endothelial cell analysis.

Time frame:
Baseline and Week 24
Reported as:
Mean · Percent change in cell density
Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at Week 24 in the Study Eye as Compared With the Fellow Eye
Percent change in cell densitySubstudy: Faricimab PTI in the Study EyeSubstudy: Fellow Eye
Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at Week 24 in the Study Eye as Compared With the Fellow Eye-0.02 (-0.86 to 0.81)-0.29 (-0.92 to 0.33)
Statistical analysis
  • Substudy: Faricimab PTI in the Study Eye vs Substudy: Fellow Eye · Paired t-test · p = 0.6305 · Mean difference (final values): 0.27 · 95% CI -0.84 to 1.38Difference is the result of study eye minus fellow eye.

Adverse events

Collected over From the date of first administration of faricimab through 28 days after the end of study (up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study Cohort A: Faricimab PTI (Prior Faricimab)13/520 (2.5%)125/520 (24%)158/520 (30.4%)
Main Study Cohort B: Faricimab PTI (Prior Aflibercept)27/505 (5.3%)156/505 (30.9%)169/505 (33.5%)
Substudy: Faricimab PTI1/113 (0.9%)14/113 (12.4%)9/113 (8%)
Most frequent serious events
Showing 10 of 232
Most frequent serious events
EventMain Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTI
Neovascular age-related macular degenerationEye disorders4/52014/5050/113
PneumoniaInfections and infestations6/5209/5050/113
COVID-19Infections and infestations8/5205/5050/113
Cardiac failure congestiveCardiac disorders6/5207/5051/113
CataractEye disorders5/5207/5050/113
FallInjury, poisoning and procedural complications4/5207/5051/113
Myocardial infarctionCardiac disorders2/5206/5050/113
Atrial fibrillationCardiac disorders3/5205/5051/113
Cerebrovascular accidentNervous system disorders5/5205/5051/113
AnaemiaBlood and lymphatic system disorders0/5201/5051/113
Most frequent other events
Most frequent other events
EventMain Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTI
CataractEye disorders56/52063/5052/113
COVID-19Infections and infestations61/52048/5055/113
Neovascular age-related macular degenerationEye disorders60/52055/5052/113
Posterior capsule opacificationEye disorders14/52026/5051/113

Baseline characteristics

The number enrolled in the GR42691 main study and overall was 1036 participants, 7 of whom were excluded from analysis as an outcome of the GCP non-compliance audit finding at one site. Therefore, 1029 participants in total were included for analysis of the main study. The GR42691 substudy enrolled a subgroup of 117 participants from the main study; 113 of those participants received at least one injection of faricimab in the study eye during the substudy and were included for analysis.

Age, Continuous
Age, Continuous(Years)Main Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTITotal
Main Study76.4 ± 8.277.7 ± 8.8—77.0 ± 8.5
Substudy——75.6 ± 8.175.6 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Main Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTITotal
Main Study — Female3082910599
Main Study — Male2162140430
Substudy — Female006161
Substudy — Male005252
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTITotal
Main Study — Hispanic or Latino50530103
Main Study — Not Hispanic or Latino4634450908
Main Study — Unknown or Not Reported117018
Substudy — Hispanic or Latino002323
Substudy — Not Hispanic or Latino009090
Substudy — Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Study Cohort A: Faricimab PTI (Prior Faricimab)Main Study Cohort B: Faricimab PTI (Prior Aflibercept)Substudy: Faricimab PTITotal
Main Study — American Indian or Alaska Native2204
Main Study — Asian76830159
Main Study — Native Hawaiian or Other Pacific Islander0000
Main Study — Black or African American1506
Main Study — White4334020835
Main Study — More than one race0101
Main Study — Unknown or Not Reported1212024
Substudy — American Indian or Alaska Native0000
Substudy — Asian0000
Substudy — Native Hawaiian or Other Pacific Islander0000
Substudy — Black or African American0011
Substudy — White00112112
Substudy — More than one race0000
Substudy — Unknown or Not Reported0000
08

Study locations

251 sites
  • Barnet Dulaney Perkins Eye Center
    Mesa, Arizona 85206, United States
  • Arizona Retina and Vitreous Consultants
    Phoenix, Arizona 85016, United States
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • Retina Associates Southwest PC
    Tucson, Arizona 85704, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • The Retina Partners
    Encino, California 91436, United States
  • South Coast Retina Center
    Los Angeles, California 90033, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • Southern CA Desert Retina Cons
    Palm Desert, California 92211, United States
  • California Eye Specialists Medical group Inc.
    Pasadena, California 91107, United States
  • Retina Consultants, San Diego
    Poway, California 92064, United States
  • Retina Consultants of Southern California
    Redlands, California 92373, United States
  • University of California, Davis, Eye Center
    Sacramento, California 95817, United States
  • Retinal Consultants Med Group
    Sacramento, California 95825, United States
  • Orange County Retina Med Group
    Santa Ana, California 92705, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • Retina Consultants of Southern
    Colorado Springs, Colorado 80909, United States
  • Colorado Retina Associates, PC
    Lakewood, Colorado 80228, United States
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
  • Rand Eye
    Deerfield Beach, Florida 33064, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Fort Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Vitreous Assoc of FL
    St. Petersburg, Florida 33711, United States
  • Southern Vitreoretinal Assoc
    Tallahassee, Florida 32308, United States
  • Retina Associates of Florida, LLC
    Tampa, Florida 33609, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina PC
    Marietta, Georgia 30060, United States
  • Retina Consultants of Hawaii
    ‘Aiea, Hawaii 96701, United States
  • Northwestern Medical Group/Northwestern University
    Chicago, Illinois 60611, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Prairie Retina Center
    Springfield, Illinois 62704, United States
  • Raj K. Maturi, MD PC
    Indianapolis, Indiana 46290, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • Retina Associates
    Lenexa, Kansas 66215, United States
  • Maine Eye Center
    Portland, Maine 04101, United States
  • Retina Specialists
    Baltimore, Maryland 21204, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Johns Hopkins Med
    Baltimore, Maryland 21287, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • VitreoRetinal Surgery, PLLC.
    Edina, Minnesota 55435, United States
  • Midwest Vision Research Foundation
    Chesterfield, Missouri 63017, United States
  • Retina Associates of St. Louis
    Florissant, Missouri 63031, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Mid Atlantic Retina - Wills Eye Hospital
    Cherry Hill, New Jersey 08034, United States
  • NJ Retina
    Edison, New Jersey 08820, United States
  • Retina Associates of NJ
    Teaneck, New Jersey 07666, United States
  • Long Is. Vitreoretinal Consult
    Great Neck, New York 11021, United States
  • Ophthalmic Cons of Long Island
    Oceanside, New York 11572, United States
  • Retina Assoc of Western NY
    Rochester, New York 14620, United States
  • Vitreoretinal Consultants of New York
    Shirley, New York 11967, United States
  • The Retina Consultants
    Slingerlands, New York 12159, United States
  • Retina Vit Surgeons/Central NY
    Syracuse, New York 13224, United States
  • Western Carolina Retinal Associate PA
    Asheville, North Carolina 28803, United States
  • Char Eye Ear &Throat Assoc
    Charlotte, North Carolina 28210, United States
  • Graystone Eye
    Winston-Salem, North Carolina 27104, United States
  • Cincinnati Eye Institute
    Blue Ash, Ohio 45242-5537, United States
  • Retina Assoc of Cleveland Inc
    Cleveland, Ohio 44122, United States
  • The Ohio State University Havener Eye Institute
    Columbus, Ohio 43212, United States
  • Midwest Retina
    Dublin, Ohio 43016, United States
  • Retina Northwest
    Portland, Oregon 97221, United States
  • Charleston Neuroscience Inst
    Ladson, South Carolina 29456, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Black Hills Eye Institute
    Rapid City, South Dakota 57701, United States
  • Southeastern Retina Associates Chattanooga
    Chattanooga, Tennessee 37421, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Tennessee Retina PC.
    Nashville, Tennessee 37203, United States
  • Retina Res Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Retina Consultants of Texas
    Houston, Texas 77030, United States
  • Valley Retina Institute P.A.
    McAllen, Texas 78503, United States
  • Retina Center of Texas
    Southlake, Texas 76092, United States
  • Retina Consultants of Houston
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah, PLLC
    Salt Lake City, Utah 84107, United States
  • Rocky Mountain Retina
    Salt Lake City, Utah 84107, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Wagner Kapoor Institute
    Norfolk, Virginia 23451, United States
  • Pacific Northwest Retina
    Silverdale, Washington 98383, United States
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • Fundacion Zambrano
    CABA, 1023, Argentina
  • Centro Oftalmologico Dr. Charles S.A.
    Capital Federal, C1116, Argentina
  • Oftalmos
    Capital Federal, C1120AAN, Argentina
  • Buenos Aires Mácula
    Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
  • Oftar
    Mendoza, M5500GGK, Argentina
  • Grupo Laser Vision
    Rosario, S2000DLA, Argentina
  • Eyeclinic Albury Wodonga
    Albury, New South Wales 2640, Australia
  • Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Sydney Retina Clinic and Day Surgery
    Sydney, New South Wales 2000, Australia
  • Sydney West Retina
    Westmead, New South Wales 2145, Australia
  • Centre For Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Retina Specialists Victoria
    Rowville, Victoria 3178, Australia
  • The Lions Eye Institute
    Nedlands, Western Australia 6009, Australia
  • LKH-Univ.Klinikum Graz
    Graz, 8036, Austria

Showing the first 100 of 251 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Sep 2024, 40 months.

Results were first posted in Oct 2025, 1 year 1 month after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 40 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 2, 2021
StartActual
Apr 19, 2021
Primary completionActual
Sep 3, 2024
CompletionActual
Sep 3, 2024
Results first posted
Oct 24, 2025
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04777201
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 2, 2021
Start date
Apr 19, 2021
Primary completion
Sep 3, 2024
Completion
Sep 3, 2024
Results posted
Oct 24, 2025
Last update
Oct 24, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion